← Human Trials & Peer-Reviewed Studies
The influence of vitamin D supplementation on melatonin status in patients with multiple sclerosis.
Plain-language guide to PMID 23665342 (2013): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 21 patients, multiple sclerosis.
Key Facts
- PMID
- 23665342
- Journal
- Brain, behavior, and immunity
- Year
- 2013
- Study type
- Randomized Controlled Trial
- Authors
- Golan D et al. (9 authors)
- DOI
- 10.1016/j.bbi.2013.04.010
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Vitamin D, K2, Magnesium and Zinc in the context of multiple sclerosis, published as a randomized controlled trial.
Multiple sclerosis (MS) incidence is higher in geographic regions with less sunlight exposure.
Both vitamin D and melatonin are essential mediators of the effect of sunlight in health, and as such are candidates to play a key role in MS.
Who Took Part
According to the abstract, 21 patients were involved.
By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.
Serum 25-hydroxy-vitamin-D (25-OH-D) and nighttime urine melatonin metabolite, 6-sulphatoxy-melatonin (6-SMT), were measured at baseline, 3 months and 1 year from enrolment.
How the Study Was Run
In design terms this was a randomized and double-blind study.
Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.
What Was Measured
The subject headings attached to it are Cholecalciferol, Data Interpretation, Statistical, Depression, Dietary Supplements, Hydroxycholecalciferols, Melatonin and Multiple Sclerosis, Relapsing-Remitting.
What This Means in Plain Language
The paper is a randomized and double-blind study of Vitamin D, K2, Magnesium and Zinc in 21 patients in people with multiple sclerosis.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2013 (Brain, behavior, and immunity), a journal based in Netherlands.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, Multiple sclerosis research.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.